Impact of Desensitization on Antiviral Immunity in HLA-Sensitized Kidney Transplant Recipients
Viral infections represent significant morbidity and mortality factors in kidney transplant recipients, with CMV, EBV, and BKV infections being most common. Desensitization (DES) with IVIg and rituximab with/without plasma exchange followed by kidney transplantation with alemtuzumab induction increa...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2017-01-01
|
| Series: | Journal of Immunology Research |
| Online Access: | http://dx.doi.org/10.1155/2017/5672523 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850173027156754432 |
|---|---|
| author | Mieko Toyoda Bong-Ha Shin Shili Ge James Mirocha David Thomas Maggie Chu Edgar Rodriguez Christine Chao Anna Petrosyan Odette A. Galera Ashley Vo Jua Choi Alice Peng Joseph Kahwaji Stanley C. Jordan |
| author_facet | Mieko Toyoda Bong-Ha Shin Shili Ge James Mirocha David Thomas Maggie Chu Edgar Rodriguez Christine Chao Anna Petrosyan Odette A. Galera Ashley Vo Jua Choi Alice Peng Joseph Kahwaji Stanley C. Jordan |
| author_sort | Mieko Toyoda |
| collection | DOAJ |
| description | Viral infections represent significant morbidity and mortality factors in kidney transplant recipients, with CMV, EBV, and BKV infections being most common. Desensitization (DES) with IVIg and rituximab with/without plasma exchange followed by kidney transplantation with alemtuzumab induction increased successful transplant rates in HLA-sensitized patients but may represent an increased risk for viral infections due to severe lymphocyte depletion. Here, we report on the posttransplant viral infection status in 372 DES versus 538 non-DES patients. CMV and EBV viremia were significantly lower in DES patients, while BKV viremia was similar. This trend was observed primarily in CMV sero(−), EBV sero(+), and sero(−) patients. No patient developed PTLD. The incidence of BKAN, allograft, and patient survival was similar in both groups. These viral infections were not associated with subsequent allograft rejection which occurred within 6 months after the infection. Conclusions. The IVIg + rituximab desensitization combined with alemtuzumab induction with triple immunosuppression maintenance does not increase the risk for CMV, EBV, and BKV infections. Possible factors include, in addition to posttransplant antiviral prophylaxis and PCR monitoring, presence of memory T cells and antibodies specific to CMV and likely EBV, NK cell-mediated ADCC despite lymphocyte depletion, elimination of EBV and CMV reservoirs by rituximab and alemtuzumab, and use of IVIg with antiviral properties. |
| format | Article |
| id | doaj-art-cbc2aab3a00b48aea14fd09dfaf2f47c |
| institution | OA Journals |
| issn | 2314-8861 2314-7156 |
| language | English |
| publishDate | 2017-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Immunology Research |
| spelling | doaj-art-cbc2aab3a00b48aea14fd09dfaf2f47c2025-08-20T02:19:57ZengWileyJournal of Immunology Research2314-88612314-71562017-01-01201710.1155/2017/56725235672523Impact of Desensitization on Antiviral Immunity in HLA-Sensitized Kidney Transplant RecipientsMieko Toyoda0Bong-Ha Shin1Shili Ge2James Mirocha3David Thomas4Maggie Chu5Edgar Rodriguez6Christine Chao7Anna Petrosyan8Odette A. Galera9Ashley Vo10Jua Choi11Alice Peng12Joseph Kahwaji13Stanley C. Jordan14Transplant Immunology Laboratory, Cedars-Sinai Medical Center, Los Angeles, CA, USATransplant Immunology Laboratory, Cedars-Sinai Medical Center, Los Angeles, CA, USATransplant Immunology Laboratory, Cedars-Sinai Medical Center, Los Angeles, CA, USABiostatistics Core, Cedars-Sinai Medical Center, Los Angeles, CA, USATransplant Immunology Laboratory, Cedars-Sinai Medical Center, Los Angeles, CA, USATransplant Immunology Laboratory, Cedars-Sinai Medical Center, Los Angeles, CA, USATransplant Immunology Laboratory, Cedars-Sinai Medical Center, Los Angeles, CA, USATransplant Immunology Laboratory, Cedars-Sinai Medical Center, Los Angeles, CA, USATransplant Immunology Laboratory, Cedars-Sinai Medical Center, Los Angeles, CA, USATransplant Immunology Laboratory, Cedars-Sinai Medical Center, Los Angeles, CA, USAComprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA, USAComprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA, USAComprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA, USAComprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA, USAComprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA, USAViral infections represent significant morbidity and mortality factors in kidney transplant recipients, with CMV, EBV, and BKV infections being most common. Desensitization (DES) with IVIg and rituximab with/without plasma exchange followed by kidney transplantation with alemtuzumab induction increased successful transplant rates in HLA-sensitized patients but may represent an increased risk for viral infections due to severe lymphocyte depletion. Here, we report on the posttransplant viral infection status in 372 DES versus 538 non-DES patients. CMV and EBV viremia were significantly lower in DES patients, while BKV viremia was similar. This trend was observed primarily in CMV sero(−), EBV sero(+), and sero(−) patients. No patient developed PTLD. The incidence of BKAN, allograft, and patient survival was similar in both groups. These viral infections were not associated with subsequent allograft rejection which occurred within 6 months after the infection. Conclusions. The IVIg + rituximab desensitization combined with alemtuzumab induction with triple immunosuppression maintenance does not increase the risk for CMV, EBV, and BKV infections. Possible factors include, in addition to posttransplant antiviral prophylaxis and PCR monitoring, presence of memory T cells and antibodies specific to CMV and likely EBV, NK cell-mediated ADCC despite lymphocyte depletion, elimination of EBV and CMV reservoirs by rituximab and alemtuzumab, and use of IVIg with antiviral properties.http://dx.doi.org/10.1155/2017/5672523 |
| spellingShingle | Mieko Toyoda Bong-Ha Shin Shili Ge James Mirocha David Thomas Maggie Chu Edgar Rodriguez Christine Chao Anna Petrosyan Odette A. Galera Ashley Vo Jua Choi Alice Peng Joseph Kahwaji Stanley C. Jordan Impact of Desensitization on Antiviral Immunity in HLA-Sensitized Kidney Transplant Recipients Journal of Immunology Research |
| title | Impact of Desensitization on Antiviral Immunity in HLA-Sensitized Kidney Transplant Recipients |
| title_full | Impact of Desensitization on Antiviral Immunity in HLA-Sensitized Kidney Transplant Recipients |
| title_fullStr | Impact of Desensitization on Antiviral Immunity in HLA-Sensitized Kidney Transplant Recipients |
| title_full_unstemmed | Impact of Desensitization on Antiviral Immunity in HLA-Sensitized Kidney Transplant Recipients |
| title_short | Impact of Desensitization on Antiviral Immunity in HLA-Sensitized Kidney Transplant Recipients |
| title_sort | impact of desensitization on antiviral immunity in hla sensitized kidney transplant recipients |
| url | http://dx.doi.org/10.1155/2017/5672523 |
| work_keys_str_mv | AT miekotoyoda impactofdesensitizationonantiviralimmunityinhlasensitizedkidneytransplantrecipients AT bonghashin impactofdesensitizationonantiviralimmunityinhlasensitizedkidneytransplantrecipients AT shilige impactofdesensitizationonantiviralimmunityinhlasensitizedkidneytransplantrecipients AT jamesmirocha impactofdesensitizationonantiviralimmunityinhlasensitizedkidneytransplantrecipients AT davidthomas impactofdesensitizationonantiviralimmunityinhlasensitizedkidneytransplantrecipients AT maggiechu impactofdesensitizationonantiviralimmunityinhlasensitizedkidneytransplantrecipients AT edgarrodriguez impactofdesensitizationonantiviralimmunityinhlasensitizedkidneytransplantrecipients AT christinechao impactofdesensitizationonantiviralimmunityinhlasensitizedkidneytransplantrecipients AT annapetrosyan impactofdesensitizationonantiviralimmunityinhlasensitizedkidneytransplantrecipients AT odetteagalera impactofdesensitizationonantiviralimmunityinhlasensitizedkidneytransplantrecipients AT ashleyvo impactofdesensitizationonantiviralimmunityinhlasensitizedkidneytransplantrecipients AT juachoi impactofdesensitizationonantiviralimmunityinhlasensitizedkidneytransplantrecipients AT alicepeng impactofdesensitizationonantiviralimmunityinhlasensitizedkidneytransplantrecipients AT josephkahwaji impactofdesensitizationonantiviralimmunityinhlasensitizedkidneytransplantrecipients AT stanleycjordan impactofdesensitizationonantiviralimmunityinhlasensitizedkidneytransplantrecipients |